Navigation Links
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Date:9/18/2007

HONOLULU, Sept. 18 Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center.

Susan Greenspan, M.D., director of the Osteoporosis Prevention and Treatment Center and Bone Health program at the University of Pittsburgh Medical Center, and colleagues evaluated 87 women, mean age 50, enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. All participants in the randomized, double-blind trial received calcium and vitamin D supplements. However, half took 35 milligrams of risedronate once a week while others took a placebo.

Chemotherapy drugs and other medical treatments for breast cancer are known to induce menopause, which can kick-start bone loss, putting survivors at risk for osteoporotic fractures, said Dr. Greenspan, an internationally respected osteoporosis researcher and professor of medicine at Pitt. This study also looked at changes in spine and hip bone mineral density, as well as evidence of bone breakdown.

Ninety-seven percent of study participants had normal or low bone mass at enrollment. At baseline, many were taking tamoxifen, a breast cancer drug aimed at estrogen-sensitive tumors that also is sometimes used as a preventive therapy by women at high risk for breast cancer.

While tamoxifen can have a positive impact on bone in postmenopausal women, a small percentage of women were taking aromatase inhibitors (also used for prevention), which can have a negative effect on bone. During the second year of the study, about half the women began taking aromatase inhibitors and stopped taking tamoxifen.

After 24 months, women in the placebo group had significant bone loss in the spine and hip that we didnt see in women taking risedronate, noted Dr. Greenspan. In fact, women taking risedronate had a bone density much higher in the spine and hip than women in the placebo group. The researchers also observed that the greatest bone loss was found in women on aromatase inhibitors. Even so, risedronate continued to be successful in preventing bone loss.

We conclude that once weekly doses of risedronate improves bone density and prevents excess bone loss in breast cancer survivors, the researchers noted.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR
3. New treatment for Osteoporosis
4. Osteoporosis in men
5. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
6. Osteoporosis Drugs: right time to take-off
7. Fluoride Found Effective in Osteoporosis
8. Cement injections linked to osteoporosis
9. Cure for osteoporosis in prostate cancer patients
10. Mutation connected to Osteoporosis
11. Osteoporosis associated with Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the top ... Living (SHSL) may not share those same worries thanks to a new bundled ... while holding the line on increasing their contributions, including premiums, deductibles and the portions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: